Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04194710
Other study ID # DA-SARC
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 22, 2020
Est. completion date December 1, 2023

Study information

Verified date December 2020
Source Corporacion Parc Tauli
Contact Laia Martínez Carreres, PhD
Phone 937231010
Email lmartinezc@tauli.cat
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to compare arthroscopic resection (surgical intervention) versus infiltration of cytokine rich serum (CRS) (proteins derived from the patient's own blood) for the treatment of lateral epicondylitis (LE).


Description:

Lateral epicondylitis (LE) is a common debilitating condition that affects the extensor muscles of the forearm at its junction with the lateral humeral epicondyle. This pathology is commonly treated by a surgical intervention. However, advances in research have allowed the discovery of new and less invasive techniques for its treatment, for example the infiltration of cytokine rich serum. The aim of the study is to compare the common treatment of this pathology, arthroscopic resection (surgical intervention) with a new technique, infiltration of cytokine rich serum (CRS) (proteins derived from the patient's own blood) with respect to medium and long-term pain reduction. The study will include a total of 86 patients. Patients will be included by randomization into two groups: - GROUP 1: 43 patients will be treated with 2 infiltrations of cytokine rich serum. - GROUP 2: 43 patients will be treated by a regular surgical treatment consisting of arthroscopic resection. The main objective of this study is to evaluate the efficacy of CRS as compared to arthroscopic resection in reducing pain in the medium term (6 months) in patients with chronic lateral epicondylitis.


Recruitment information / eligibility

Status Recruiting
Enrollment 86
Est. completion date December 1, 2023
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Over 18 years of age - Patients with persistent pain (EVA > 5) at lateral epicondyle level of at least 3 months duration. - Patients with a diagnosis of chronic lateral epicondylitis confirmed with a complementary diagnostic test such as Echo or MRI. - Availability to follow the study protocol for up to 24 months. - Patients with the ability to understand study information and give informed consent. - Patients who sign informed consent. - Normal hematologic parameters. Exclusion Criteria: - Local infection present. - Patients who have been treated with corticosteroid infiltrations in the same area in the past 4 months. - Patients who have received treatment with growth factors, PRP, cytokines, or new drug treatments in the same area in the last 12 months. - Pregnancy or breast-feeding. - Neoplastic disease. - Patients being treated with immunosuppressants (medical evaluation). - Patients undergoing arthroscopic surgery of the same elbow. - Active liver disease. - Immunosuppressive or immunodeficiency states. - Coagulation deficit or abnormalities. - Thrombocytopenia. - Treatment with anticoagulants. - Difficulty understanding and following study procedures. - Participation in a clinical trial with medications.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Autologous Cytokine Rich Serum
Proteins, called cytokines, released from blood platelets and leukocytes, play an important role in the repair and regeneration of the injured tissue that causes lateral epicondylitis. Autologous Cytokine Rich Serum is prepared by the medical devise Q-Cytokine (CE MED31489) from patient's blood. The company Tecnologia Regenerativa Qrem S.L., with licence number 7096-PS from Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), is the manufacturer of this product. Q-Cytokine is a lab-in-a-box devise, and consist of an automatic centrifuge and a sterile disposable kit. After 9 steps of centrifugation, that take place in 36 minutes, Cytokine Rich Serum is obtained. This Cytokine Rich Serum is then injected to the epicondyle. Patients randomized to this treatment will receive 1 injections of Autologous Cytokine Rich Serum right after randomization and another one after 15 days. This process will take place at outpatient clinics.
Procedure:
Arthroscopic Resection
Surgical treatment of resection by arthroscopy is the standard treatment for chronic epicondylitis. The surgery is performed in the operating room under local anesthesia and lasts approximately 30 minutes. During the surgery, the doctor accesses the tendon by arthroscopy to perform an exeresis of the degenerated tendon. After the operation, the patient is directed to the recovery room where the responsible doctor will perform a physical examination and examination before leaving the center. This process will take place at the major ambulatory surgery center of the investigator's hospital.

Locations

Country Name City State
Spain Hospital Clínic i Provincial de Barcelona Barcelona
Spain Corporació Sanitària Parc Taulí Sabadell Barcelona

Sponsors (2)

Lead Sponsor Collaborator
Corporacion Parc Tauli Tecnologia Regenerativa Qrem S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain assessment reduction of pain to 6 months measured with the Visual Analogue Scale (EVA) scale. The specification of the efficacy parameter is an absolute improvement of the 2-point scale. 6 months
Secondary Pain assessment with Visual Analogue Scale (EVA) scale Visual Analogue Scale (EVA) from 0 to 10 points, being 0 no pain, and 10 maximum pain 15 days, 1-3-12-24 months after intervention
Secondary Patient-Related Tennis Elbow Evaluation (PRTEE) The Patient-Rated Tennis Elbow Evaluation questionnaire (PRTEE) is a specific questionnaire available for assessing the health status of patients with lateral epicondylitis. It is a is a 15-item questionnaire allows patients to rate their levels of tennis elbow pain and disability from 0 to 10, and consists in two subscales:
PAIN subscale (0 = no pain, 10 = worst imaginable) - 5 items
FUNCTION subscale (0 = no difficulty, 10 = unable to do) Specific activities - 6 items Usual activities - 4 items
15 days, 1-3-6-12-24 months after intervention
Secondary Grip force measured with a palm grip dynamometer, in kilos 15 days, 1-3-6-12-24 months after intervention
Secondary occurrence of pain with resisted wrist extension assessed during medical examination 15 days, 1-3-6-12-24 months after intervention
Secondary Number of participants with complications related to the treatment assessed during medical examination 15 days, 1-3-6-12-24 months after intervention
Secondary Revision of anti-inflammatory medication and its dose assessed during medical examination 15 days, 1-3-6-12-24 months after intervention
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05238090 - Efficacy of a Stretching Protocol for Lateral Epicondylitis N/A
Recruiting NCT06442618 - Effectiveness of Extracorporeal Shockwave Therapy and Nutraceutical Supplementation in the Treatment of Epicondylitis: a Clinical Trial N/A
Completed NCT04026191 - OVT for Epicondylosis (Tennis Elbow) N/A
Completed NCT04875338 - Injection in the Treatment of Lateral Epicondylitis. Randomized Controlled Trial Phase 3
Completed NCT06160011 - Epicondylar Muscle Activation in Tennis Players N/A